Biophytis Advances DMD Treatment with BIO101 Scale-Up
Company Announcements

Biophytis Advances DMD Treatment with BIO101 Scale-Up

Biophytis (BPTSY) has released an update.

Biophytis, a clinical-stage biotech company, has announced the successful scale-up of BIO101 production with Seqens, marking a significant advancement in the treatment of Duchenne Muscular Dystrophy (DMD). The first GMP-compliant batch of their lead drug candidate is now ready for use in upcoming clinical trials aimed at improving respiratory function in patients. The company is poised to start a phase 1-2 clinical trial and is actively seeking partners and funding to further this endeavor.

For further insights into BPTSY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBiophytis Advances Clinical Trials and Targets $100B Market
TipRanks Auto-Generated NewsdeskBiophytis Targets Obesity with Phase 2 Study Filing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App